Anti-RASSF1 Rabbit Polyclonal Antibody for WB and ELISA - Q9NS23

Core Product Specifications and Parameters

Biological Background: RASSF1 Function and Localization

• RASSF1 is a potential tumor suppressor required for death receptor-dependent apoptosis. It mediates activation of STK3/MST2 and STK4/MST1 during Fas-induced apoptosis by preventing their dephosphorylation.
• Upon association with MOAP1, RASSF1 promotes BAX conformational change and translocation to mitochondrial membranes in response to TNF and TNFSF10 stimulation.
• Isoform A interacts with CDC20, an activator of the anaphase-promoting complex (APC), inhibiting APC activity and mitotic progression. It also inhibits proliferation by regulating cyclin D1 accumulation at the G1/S-phase transition.
• Isoform A disrupts the MDM2-DAXX-USP7 interaction, promoting MDM2 self-ubiquitination and contributing to efficient TP53 activation in cell-cycle checkpoint control following DNA damage.
• The protein localizes to the cytoplasm, cytoskeleton (including microtubules, centrosome, spindle, and spindle pole), and nucleus.
• Isoforms A and C are ubiquitously expressed in all tissues tested, but isoform A is frequently absent in cancer cell lines. Isoform B is mainly expressed in hematopoietic cells.
• Key post-translational modifications include acetylation, methylation, and phosphorylation. The protein contains a zinc-finger domain and binds zinc.
• Alternative splicing and alternative promoter usage produce multiple isoforms, and the gene is subject to epigenetic silencing in many cancers.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 101–340 of human RASSF1 (isoform A), encompassing critical functional domains. Consider verifying isoform specificity using positive controls expressing known RASSF1 variants.
• For Western blot analysis, whole cell lysates from human or mouse tissues/cell lines expressing RASSF1 should yield a band near 39 kDa. Note that post-translational modifications may cause slight mobility shifts.
• In ELISA, using the recombinant protein or peptide derived from the immunogen region as coating antigen can help confirm antibody recognition. Validate assay conditions with appropriate positive and negative controls.
• Given that RASSF1 is frequently silenced by promoter methylation in cancer, treatment with demethylating agents (e.g., 5-aza-2'-deoxycytidine) before lysate preparation may be necessary for detection in certain cell lines.
• This antibody has been shown to react with human and mouse samples; cross-reactivity with other species should be determined empirically.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your one-stop sourcing bridge for IVD raw materials, providing diagnostic manufacturers, labs, and research institutes with validated antibody pairs, optimized polyclonal and monoclonal antibodies, and bulk ancillary reagents. For tumor suppressor research and cell cycle/apoptosis studies, we can facilitate sourcing of rare-target raw materials such as RASSF1 antibodies and related products, supporting your workflow from concept to clinical application.